Market Place
Sourcing Support
FDA Accepts Zipalertinib NDA for EGFR Exon 20 NSCLC Cancer
28 Apr 2026 //
PHARMIWEB
Cullinan Therapeutics Updates Pipeline, Reports 2025 Results
10 Mar 2026 //
GLOBENEWSWIRE
Cullinan Therapeutics To Join Investor Conferences
24 Feb 2026 //
GLOBENEWSWIRE
Cullinan Oncology Joins Citi`s 2026 Fireside Chat
18 Feb 2026 //
GLOBENEWSWIRE
Cullinan Therapeutics Joins Fireside Chat At Guggenheim Biotech
05 Feb 2026 //
GLOBENEWSWIRE
Cullinan Pharma Updates On Corporate Progress, 2026 Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Cullinan Presents CLN-049 AML Data at 67th ASH Meeting
08 Dec 2025 //
GLOBENEWSWIRE
Cullinan Receives FDA Fast Track Designation for CLN-049
01 Dec 2025 //
GLOBENEWSWIRE
Taiho, Cullinan Start NDA Submission For Zipalertinib In NSCLC
20 Nov 2025 //
PR NEWSWIRE
Cullinan Therapeutics To Present At Investor Conferences
10 Nov 2025 //
GLOBENEWSWIRE
Cullinan Therapeutics Presents Strong Clinical Data On CLN-049
03 Nov 2025 //
GLOBENEWSWIRE
Cullinan Therapeutics Presents Preclinical Data On CLN-978
25 Oct 2025 //
GLOBENEWSWIRE
Taiho Oncology, Cullinan Therapeutics Present Zipalertinib Data
13 Oct 2025 //
PR NEWSWIRE
Cullinan, Taiho`s NSCLC Shows `Strong Activity`, Paves Way to FDA
10 Sep 2025 //
BIOSPACE
Taiho & Cullinan Present Zipalertinib Data at IASLC Conference
09 Sep 2025 //
PR NEWSWIRE
Disc Medicine Reports Q2 2025 Financials and Updates on Business
07 Aug 2025 //
GLOBENEWSWIRE
Taiho Oncology, Cullinan Therapeutics` Zipalertinib abstracts
22 Jul 2025 //
PR NEWSWIRE
Cullinan`s $700 M Pact for BCMA Bispecific to Pair with Other TCE
05 Jun 2025 //
FIERCE BIOTECH
Cullinan Therapeutics Licenses Velinotamig from Genrix Bio
04 Jun 2025 //
GLOBENEWSWIRE
Taiho & Cullinan Announce Phase 1/2 Data Published
01 Jun 2025 //
PR NEWSWIRE
Cullinan, Taiho, and Taiho Oncology to Present Zipalertinib Trial
22 May 2025 //
GLOBENEWSWIRE
Cullinan Therapeutics Updates on Q1 2025 Financial Results
08 May 2025 //
GLOBENEWSWIRE
Cullinan Therapeutics to Study CLN-978 in Sjögren’s Disease in US
29 Apr 2025 //
GLOBENEWSWIRE
Cullinan Joins Fireside Chat At Guggenheim Biotech Conference
30 Jan 2025 //
GLOBENEWSWIRE
Cullinan Presents CLN-978 Preclinical Data at ACR Convergence
14 Nov 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics to CLN-978 Data at ACR Convergence 2024
04 Nov 2024 //
GLOBENEWSWIRE
Cullinan Receives FDA Clearance For CLN-978 In Lupus Erythematosus
16 Oct 2024 //
GLOBENEWSWIRE
Cullinan Therapeutics Presents Zipalertinib Phase 2b Data At ESMO 2024
14 Sep 2024 //
GLOBENEWSWIRE
Cullinan Returns Bispecific To Harbour BioMed After $25M US Rights Deal
08 Aug 2024 //
FIERCE BIOTECH
Cullinan Cln-619 First Data: Anti-Mica/B With Cpi At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Cullinan Presents CLN-619 Combo Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Cullinan Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617
14 Dec 2023 //
GLOBENEWSWIRE
Cullinan Oncology Announces First Patient Dosed in Phase 1 Evaluating CLN-978
09 Aug 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619
25 May 2023 //
GLOBENEWSWIRE
Cullinan Oncology Announces U.S. FDA Clearance of IND Application for CLN-617
27 Mar 2023 //
GLOBENEWSWIRE
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617
14 Mar 2023 //
GLOBENEWSWIRE
Cullinan Oncology Announces U.S. FDA Clearance of IND Application for CLN-978
24 Jan 2023 //
GLOBENEWSWIRE
